news
Scientists discover multiple pathways of the 5HT2a receptor activated by psychedelics
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
List view / Grid view
Depression
article
Innovative treatments: the new frontier for mental health
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
news
Intranasal drug may be the future of depression treatments
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
news
Psilocybin spurs growth of neural connections lost in depression in vivo
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
news
Multi-omics approach identifies genes associated with alcohol use disorder
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
news
Common antidepressant drugs fight cancer in mice, study shows
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
news
Non-hallucinogenic version of ibogaine could treat addiction and depression
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
news
New insight to guide discovery of drugs targeting ion channels
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
news
Novel antibody treatment for OCD demonstrates efficacy in mice
Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
news
New compound could alleviate side effects of antidepressant drugs
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
article
Safer and more affordable medicine for all? How pharmacogenomics may level the playing field
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
article
Novel molecules to adjust the circadian rhythm
A collaborative team of researchers has discovered two molecules that target the melatonin receptor, responsible for regulating the circadian rhythm. This article delves into their study and its therapeutic relevance for the body clock.
news
Neuronal link between chronic pain and depression discovered
The mechanism in the brain connecting chronic pain and depression could lead to treatments for both, according to researchers.
news
Researchers identify potential drug target for depression in primates
A study has discovered a molecule key in neuronal growth that could be used as a drug target to treat anxiety-related diseases.
news
New drug target for depression identified
Researchers find key molecule in depression and identify new therapeutic targets.